Wegovy 7.2 mg single-dose pen
Launched in the UK in June 2026; EU rollout planned for the second half of 2026.
What it is
Higher-dose Wegovy in a single-dose pen. It is the company's next step in injectable weight-loss dosing, with EMA approval in July 2026.
Why it matters to the stock. A higher dose may keep injectable patients on Wegovy, which protects the franchise against the oral pill and rival drugs.
News
Novo to present 44 abstracts at EASD 2026 including Wegovy pill real-world data
Novo said it will present 44 abstracts at the EASD 2026 diabetes meeting in Milan from 28 September to 2 October, covering semaglutide, CagriSema and zenagamtide.
EU approves Wegovy pill as first oral GLP-1 for weight management
The European Commission granted marketing authorisation for the Wegovy pill, once-daily oral semaglutide 25 mg, for adults with obesity or with overweight plus at least one weight-related condition.
Wegovy HD (7.2 mg) launches in the US in a single-dose pen
Novo Nordisk launched Wegovy HD, the 7.2 mg weekly injection, in the US in April 2026, after the March FDA approval.
FDA approves Wegovy HD (7.2 mg) with 20.7% mean weight loss
The US FDA approved Wegovy HD, a once-weekly 7.2 mg semaglutide injection, to reduce excess body weight and maintain the loss long term.